SCHEMBL23385296

SCHEMBL23385296

O=C(NC1CCCC1)c1cc(F)cc(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.58
RAB9A P51151 5/20 0.58
GRM5 P41594 4/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HTR2B P41595 1/20 0.49
KDM4E B2RXH2 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MLLT1 Q03111 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
CYP1A2 P05177 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16236344 0.94 SMYD3 (0.51) NPC1RAB9AGRM5MEN1KMT2A
SCHEMBL2825577 0.81 SMYD3 (0.58) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL1518413 0.81 SMYD3 (0.58) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL2476158 0.81 NPC1 (0.56) NPC1RAB9AGRM5MEN1KMT2A
SCHEMBL16143001 0.81 RAB9A (0.60) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL23360960 0.81 NPC1 (0.58) NPC1RAB9AGRM5MEN1KMT2A
SCHEMBL16143123 0.80 NPC1 (0.62) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL15219382 0.80 NPC1 (0.62) NPC1RAB9AGRM5MEN1KMT2A
SCHEMBL10212630 0.80 HRH3 (0.46) NPC1RAB9AGRM5
SCHEMBL11919303 0.80 RAB9A (0.56) NPC1RAB9AGRM5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230050653-A1 ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-02-16 US disclosed
EP-4059928-A1 ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Wuhan LL Science and Technology Development Co., Ltd. (CN) 2022-09-21 EP disclosed
CN-114728926-A ROCK inhibitor and preparation method and application thereof 武汉朗来科技发展有限公司 2022-07-08 CN disclosed
WO-2021093795-A1 ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 武汉朗来科技发展有限公司 2021-05-20 WO disclosed
WO-2021093795-A1 ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 武汉朗来科技发展有限公司 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230050653-A1 ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF ROCK1, CYP11B1, CYP4A11 NPC1 934/4885RAB9A 343/4885GRM5 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.